Live price temporarily unavailable.
Dermata Therapeutics (DRMA) is a Health Care company. Latest news and coverage below.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Operating income | −$3.17M | −$7.86M | −$9.67M | −$8.04M | −$12.5M | −$7.77M |
| Net income | −$3.24M | −$7.90M | −$9.61M | −$7.79M | −$12.3M | −$7.56M |
| EPS (diluted) | — | — | — | −$399.90 | −$80.32 | −$8.16 |
| Balance sheet | ||||||
| Cash and equivalents | $530.4K | $10.8M | $6.24M | $7.44M | $3.16M | $7.52M |
| Total assets | $605.5K | $11.6M | $6.94M | $7.98M | $3.53M | $7.86M |
| Total liabilities | $3.78M | $1.52M | $922.6K | $1.62M | $1.97M | $1.64M |
| Shareholders' equity | −$3.18M | $10.1M | $6.02M | $6.36M | $1.56M | $6.22M |
| Cash flow | ||||||
| Operating cash flow | −$4.03M | −$5.69M | −$8.83M | −$6.41M | −$11.2M | −$7.76M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$3.23M | −$3.20M | −$2.34M | −$1.77M | −$1.76M | −$1.90M | −$1.93M | −$3.01M |
| Net income | −$3.17M | −$3.15M | −$2.30M | −$1.70M | −$1.69M | −$1.86M | −$1.85M | −$2.97M |
| EPS (diluted) | −$204.10 | $612.58 | −$4.47 | −$1.66 | −$16.50 | $14.47 | −$0.48 | −$0.74 |
| Balance sheet | ||||||||
| Cash and equivalents | $6.14M | $3.16M | $9.72M | $6.48M | $4.66M | $7.52M | $6.95M | $4.41M |
| Total assets | $6.69M | $3.53M | $10.0M | $6.64M | $5.07M | $7.86M | $7.47M | $5.32M |
| Total liabilities | $1.95M | $1.97M | $2.70M | $1.03M | $1.11M | $1.64M | $1.05M | $1.83M |
| Shareholders' equity | $4.74M | $1.56M | $7.30M | $5.61M | $3.96M | $6.22M | $6.41M | $3.49M |
| Cash flow | ||||||||
| Operating cash flow | −$3.42M | −$2.91M | −$1.93M | −$2.69M | −$1.80M | −$1.33M | −$2.48M | −$2.42M |
From Dermata Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Dermata Therapeutics in our feed yet.